Beijing's BeiGene to Build Manufacturing Facility in Suzhou

BeiGene, a Beijing biopharma developing novel oncology drugs, plans to build a cGMP manufacturing facility in Suzhou's BioBAY. The 97,000 square feet facility, which is expected to be completed in 2017, will supply products for clinical trials and commercial sale. BeiGene currently lists eleven molecules in development, three of them in proof-of-concept trials. Its portfolio is focused on targeted and immuno-oncology therapeutics. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.